329 related articles for article (PubMed ID: 15161712)
1. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
5. Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
Yokoyama T; Miyazawa K; Yoshida T; Ohyashiki K
Int J Oncol; 2005 Jan; 26(1):33-40. PubMed ID: 15586222
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
[TBL] [Abstract][Full Text] [Related]
7. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.
Litz J; Sakuntala Warshamana-Greene G; Sulanke G; Lipson KE; Krystal GW
Lung Cancer; 2004 Dec; 46(3):283-91. PubMed ID: 15541812
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
9. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of imatinib in patients with small cell lung cancer.
Johnson BE; Fischer T; Fischer B; Dunlop D; Rischin D; Silberman S; Kowalski MO; Sayles D; Dimitrijevic S; Fletcher C; Hornick J; Salgia R; Le Chevalier T
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5880-7. PubMed ID: 14676110
[TBL] [Abstract][Full Text] [Related]
11. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
Shaw TJ; Vanderhyden BC
Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
[TBL] [Abstract][Full Text] [Related]
12. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
Attoub S; Rivat C; Rodrigues S; Van Bocxlaer S; Bedin M; Bruyneel E; Louvet C; Kornprobst M; André T; Mareel M; Mester J; Gespach C
Cancer Res; 2002 Sep; 62(17):4879-83. PubMed ID: 12208734
[TBL] [Abstract][Full Text] [Related]
13. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
Knight B; Tirnitz-Parker JE; Olynyk JK
Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
[TBL] [Abstract][Full Text] [Related]
14. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Krystal GW; DeBerry CS; Linnekin D; Litz J
Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619
[TBL] [Abstract][Full Text] [Related]
15. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
16. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.
Krystal GW; Hines SJ; Organ CP
Cancer Res; 1996 Jan; 56(2):370-6. PubMed ID: 8542594
[TBL] [Abstract][Full Text] [Related]
17. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
Krystal GW; Honsawek S; Kiewlich D; Liang C; Vasile S; Sun L; McMahon G; Lipson KE
Cancer Res; 2001 May; 61(9):3660-8. PubMed ID: 11325836
[TBL] [Abstract][Full Text] [Related]
18. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
20. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling.
Khanzada UK; Pardo OE; Meier C; Downward J; Seckl MJ; Arcaro A
Oncogene; 2006 Feb; 25(6):877-87. PubMed ID: 16170339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]